Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration.

Authors:
Shikha Mishra
Shikha Mishra
I.T.S. Paramedical (Pharmacy) College
India
Shaurya Joshi
Shaurya Joshi
University of Miami Miller School of Medicine
Jennifer E Ward
Jennifer E Ward
School of Electrical
Aurangabad | India
Deepak Mishra
Deepak Mishra
Indira Gandhi Institute of Medical Sciences
India
Deepa Mishra
Deepa Mishra
The University of Utah
United States
Isabel Morgado
Isabel Morgado
Institute of Medical Physics and Biophysics
Germany
Sudeshna Fisch
Sudeshna Fisch
Brigham and Women's Hospital

Am J Physiol Heart Circ Physiol 2019 May 15;316(5):H1158-H1166. Epub 2019 Mar 15.

Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, Massachusetts.

Cardiac dysfunction is the most frequent cause of morbidity and mortality in amyloid light chain (AL) amyloidosis caused by a clonal immunoglobulin light chain (LC). Previously published transgenic animal models of AL amyloidosis have not recapitulated the key phenotype of cardiac dysfunction seen in AL amyloidosis, which has limited our understanding of the disease mechanisms in vivo, as well as the development of targeted AL therapeutics. We have developed a transgenic zebrafish model in which a λ LC derived from a patient with AL amyloidosis is conditionally expressed in the liver under the control of the Gal4 upstream activation sequence enhancer system. Circulating LC levels of 125 µg/ml in these transgenic zebrafish are comparable to median pathological serum LC levels. Functional analysis links abnormal contractile function with evidence of cellular and molecular proteotoxicity in the heart, including increased cell death and autophagy. However, despite pathological and functional phenotypes analogous to human AL, the lifespan of the transgenic fish is comparable to control fish without the expressed AL-LC transgene. Nuclear labeling experiments suggest increased cardiac proliferation in the transgenic fish, which can be counteracted by treatment with a small molecule proliferation inhibitor leading to increased zebrafish mortality because of cardiac apoptosis and functional deterioration. This transgenic zebrafish model provides a platform to study underlying AL disease mechanisms in vivo further. Heart failure is a major cause of mortality in amyloid light (AL) amyloidosis, yet it has been difficult to model in animals. We report the generation of a transgenic zebrafish model for AL amyloidosis with pathological concentration of circulating human light chain protein that results in cardiac dysfunction. The light chain toxicity triggers regeneration in the zebrafish heart resulting in functional compensation early in life, but with age develops into cardiac dysfunction.

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajpheart.00788.2018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580397PMC

Still can't find the full text of the article?

We can help you send a request to the authors directly.
May 2019

Publication Analysis

Top Keywords

light chain
20
cardiac dysfunction
16
zebrafish model
16
transgenic zebrafish
16
amyloid light
12
disease mechanisms
8
transgenic fish
8
mortality amyloid
8
mechanisms vivo
8
transgenic
7
zebrafish
7
amyloidosis
6
cardiac
6
light
6
chain
5
comparable control
4
control fish
4
human lifespan
4
phenotypes analogous
4
analogous human
4

Altmetric Statistics

References

(Supplied by CrossRef)

Similar Publications